UroGen Pharma Ltd.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- UroGen Pharma Ltd. is a biotechnology firm dedicated to advancing innovative therapeutic options for specific cancers and conditions affecting the urothelium. The company leverages its proprietary RTGel, a unique polymeric, reverse-thermal hydrogel, which transforms from a liquid into a gel at body temperature, to enhance the delivery and sustained exposure of therapeutic agents. Among its commercial offerings is Jelmyto, a mitomycin-based pyelocalyceal solution, specifically indicated for the treatment of low-grade upper tract urothelial carcinoma (LG-UTUC). More recently, the company expanded its portfolio with the FDA approval of ZUSDURI™ (mitomycin) for intravesical solution, addressing recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The development pipeline includes UGN-103, a next-generation mitomycin formulation utilizing the RTGel technology, currently progressing towards a Phase 3 study for LG-IR-NMIBC, with the FDA having agreed to an NDA submission strategy for the second half of 2026. Another advanced candidate, UGN-104, also a mitomycin-based formulation, is anticipated to commence Phase 3 trials in early 2025 for LG-UTUC. Beyond these, UroGen is exploring UGN-301, an anti-CTLA-4 monoclonal antibody administered intravesically in Phase 1 trials for high-grade non-muscle invasive bladder cancer (HG-NMIBC). The company is also developing UGN-501, an investigational oncolytic virus, with IND-enabling studies projected to begin in 2025. UroGen maintains strategic collaborations, including a license and supply agreement with medac GmbH for next-generation mitomycin-based formulations, potentially extending patent protection for these programs until 2041. The company was established in 2004 and is headquartered in Princeton, New Jersey, with active operations in Israel.
Company News
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma to Present at Upcoming Investor Conferences
BlackRock Inc. Purchases Shares of 3,201,461 Urogen Pharma $URGN
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
Urogen Pharma Q2 Earnings Call Highlights
UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
ADAR1 Capital Management LLC Boosts Stock Position in Urogen Pharma $URGN
UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?